VAL-083 combination therapies in chemo-resistant pediatric CNS cancers

More children die from brain cancer than from any other disease in the western world. Many anti-cancer drugs are unable to cross the blood-brain barrier to reach the tumor and certain genetic mutations in the tumor cells increase resistance to chemotherapeutics. The novel chemotherapeutic drug VAL-083 readily crosses the blood-brain barrier and accumulates in brain tumor tissues and has documented activity against pediatric brain tumors in historical clinical trials.